ES2156853T3 - Derivados de quinolina. - Google Patents

Derivados de quinolina.

Info

Publication number
ES2156853T3
ES2156853T3 ES91117581T ES91117581T ES2156853T3 ES 2156853 T3 ES2156853 T3 ES 2156853T3 ES 91117581 T ES91117581 T ES 91117581T ES 91117581 T ES91117581 T ES 91117581T ES 2156853 T3 ES2156853 T3 ES 2156853T3
Authority
ES
Spain
Prior art keywords
sub
group
alkoxi
whole
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91117581T
Other languages
English (en)
Inventor
Hiroshi Hasegawa
Kazuo Isomae
Takeshi Kotsugai
Noriaki Shioiri
Kumiko Sekine
Naokata Taido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SSP Co Ltd
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Application granted granted Critical
Publication of ES2156853T3 publication Critical patent/ES2156853T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DERIVADOS DE QUINOLINA DE LA FORMULA: DONDE <A --ENTA UN GRUPO <N-(CH SUB 2) SUB N-, <C=, <C=CH(CH SUB 2) SUB N-, O <CH(CH SUB 2) SUB N-, DONDE N ES UN ENTERO DE 0 A 7; Y REPRESENTA UN GRUPO <C=O O <CHOH, R ELEVADO 1 ES UN ATOMO DE HIDROGENO, UNO DE HALOGENO, UN GRUPO ALCALINO, ALKOXI O DE ALKILTIO, R (AL CUADRADO) ES UN ATOMO DE HIDROGENO, DE HALOGENO, UN GRUPO ALCALINO, DE HIDROXI, DE ALKOXI, DE FENILO QUE PUEDE TENER UN SUSTITUTO, UN GRUPO FENOXI, ALKANOILOXI, O UN GRUPO DE AMINAS QUE PUEDEN TENER SUSTITUTOS, R ELEVADO 3 ES UN ATOMO DE HIDROGENO, DE HALOGENO, UN GRUPO ALCALINO O ALKOXI Y M ES UN ENTERO DE 1 A 3. LOS COMPUESTOS Y SUS SALES EXHIBEN UNA ACTIVIDAD ANTI-ACETILCOLINESTERASA SUPERIOR SIN EFECTOS LATERALES Y SON EFECTIVAS PARA LA PREVENCION O CURA DE LA DEMENCIA SENIL O DE LAS PERTURBACIONES DE LA MEMORIA.
ES91117581T 1990-10-19 1991-10-15 Derivados de quinolina. Expired - Lifetime ES2156853T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28109390 1990-10-19
JP28109490 1990-10-19

Publications (1)

Publication Number Publication Date
ES2156853T3 true ES2156853T3 (es) 2001-08-01

Family

ID=26554052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91117581T Expired - Lifetime ES2156853T3 (es) 1990-10-19 1991-10-15 Derivados de quinolina.

Country Status (7)

Country Link
US (2) US5190951A (es)
EP (2) EP0481429B1 (es)
KR (1) KR100206200B1 (es)
CA (1) CA2053640C (es)
DE (1) DE69132519T2 (es)
ES (1) ES2156853T3 (es)
SG (1) SG44523A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
DE69617237T2 (de) * 1995-06-15 2002-06-27 Pharmacia & Upjohn Co., Kalamazoo Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel
IL139254A0 (en) * 1998-06-10 2001-11-25 Arena Pharm Inc Acetylcholine enhancers
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
KR100648869B1 (ko) 1998-09-30 2007-02-28 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
US6800625B2 (en) 2002-06-19 2004-10-05 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
AU2006327300A1 (en) * 2005-12-20 2007-06-28 Astrazeneca Ab Substituted Cinnoline derivatives as GABAa-receptor modulators and method for their synthesis
AR067028A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Compuestos y usos de los mismos 849
AR067027A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a.
EA202092673A3 (ru) * 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
CN102875602B (zh) * 2012-10-25 2015-05-20 江苏神龙药业有限公司 一种米诺膦酸水合物的制备方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112608326B (zh) * 2021-01-22 2021-10-01 河南大学 呋喃并[2,3-b]喹啉-3,4（2H,9H)-二酮衍生物、其制备方法及应用
CN114989180B (zh) * 2022-05-26 2024-06-04 广东海洋大学 杨叶肖槿内生真菌来源的化合物及其制备方法与应用
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2507076B2 (ja) * 1989-08-11 1996-06-12 株式会社クボタ カ―ド式自動販売機
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5240934A (en) * 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives

Also Published As

Publication number Publication date
KR100206200B1 (ko) 1999-07-01
EP0481429A3 (en) 1992-08-19
DE69132519D1 (de) 2001-03-01
CA2053640C (en) 2001-12-25
DE69132519T2 (de) 2001-06-13
US5190951A (en) 1993-03-02
EP0987262A1 (en) 2000-03-22
KR920008024A (ko) 1992-05-27
CA2053640A1 (en) 1992-04-20
SG44523A1 (en) 1997-12-19
EP0481429B1 (en) 2001-01-24
EP0481429A2 (en) 1992-04-22
US5300517A (en) 1994-04-05
HK1011351A1 (en) 1999-07-09

Similar Documents

Publication Publication Date Title
ES2156853T3 (es) Derivados de quinolina.
NO914092L (no) Nye mercaptoacetylamid-derivater som er anvendbare som inhibitorer for enkefalinase og ace
NO923744D0 (no) Nye 2-substituerte indan-2-mercaptoacetylamidderivater anvendbare som inhibitorer av enkefalinase og ace
NO892851L (no) Fremstilling og anvendelse av qkuinolinderivater.
NO923745L (no) Nye 2-substituerte indan-2-carboxyalkylderivater anvendbare som inhibitorer av enkefalinase og ace
DE3480393D1 (de) Guanidin derivatives
ES2029786T3 (es) Procedimiento para preparar nuevos derivados de quinolina.
FI891548A0 (fi) Administrering av monoaminakridiner i kolinergiska bristtillstaond av nervceller.
NO980856D0 (no) Piperazinderivater og fremgangsmåte for fremstilling derav
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
DK519985D0 (da) Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater
ATE40358T1 (de) 2,3-dihydrobenzofuran-derivate, mehrere verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
ES8600243A1 (es) Procedimiento para la obtencion de compuestos de 2-hidroximetil-3-carbamoil-1,4-dihidropiridina
ES2063756T3 (es) Derivados de acido benzoilaminofenoxibutanoico.
DK26289D0 (da) Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
ES8604922A1 (es) Procedimiento para la preparacion de n-piridilindoles
ES8604543A1 (es) Procedimiento para la obtencion de derivados piperazinicos
MY101142A (en) 1, 4-dihydropyridine derivative, process for production thereof, and pharmaceutical use thereof.
DK671588A (da) Bisphenylalkylpiperazinderivater og fremgangsmaade til fremstilling deraf
ES2056795T3 (es) Pirrolidin- y piperidinderivados n-substituidos y sus sales.
AR240825A2 (es) Procedimiento para obtener compuestos de 7-(2-aminotiazol-4-il-acetamido-3(((1-(2-dimetil aminoetil)-1h-tetrazol-5-il)tio)metil)-cef-3-em-4-carboxilato y sus sales
ES2158290T3 (es) Derivados de tiazolidinona opticamente activos.
ES2073460T3 (es) Fenilalquilaminas y los fungicidas que las contienen.
ES2038194T3 (es) Procedimiento para la obtencion de derivados de la benzhidriloxietil-piperidina.
BG60248B2 (en) Process for the preparation of phenoxyethylamine derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 481429

Country of ref document: ES